Mental Health Watchdog Calling for Investigation into Psychiatric Drugging of Millions of Children

Psychiatric Drugging of Children

Currently 8 million U.S. children are being prescribed psychiatric drugs, with more than 1 million between the ages of zero to five.

Children are being drugged simply because psychiatry has reclassified normal childhood behaviors and repackaged them as 'mental disorders' resulting in the psychiatric drugging of millions of kids.”

— CCHR

CLEARWATER, FLORIDA, UNITED STATES, December 18, 2017 /EINPresswire.com/ — The Citizens Commission on Human Rights (CCHR) of Florida, a non-profit mental health watchdog dedicated to protection of children, is calling for an investigation into the heavy psychiatric drugging of children; especially foster children, in Florida.

A report from the research arm of Florida's child-protection system released in 2015 showed that foster children are being put on psychotropic medications without caregivers following proper procedures and that 11 percent of the children in foster care had active prescriptions for at least one psychotropic drug. While a review of 140 children's files showed just 20 percent of these children met all the key requirements for administering such medication.

Following the tragic death of 7-year-old Gabriel Myers in 2009, who was found hanging from a shower fixture in his foster home after having been prescribed two “black box” drugs intended for adults – the Florida policies for using psychotropic drugs on foster kids were updated but this has not solved the problem.

The psychiatric drugging of children is not just confined to the foster care system. In 2011 a two-year investigation concluded that kids in Florida, Massachusetts, Michigan, Oregon and Texas were “prescribed psychotropic drugs at rates 2.7 to 4.5 times higher than other children in Medicaid in 2008.”

Currently 8 million U.S. children are being prescribed psychiatric drugs, with more than 1 million between the ages of zero to five. Children are being drugged simply because psychiatry has pathologized normal childhood behaviors, and repackaged them as “mental disorders.” The result is that millions of children are being drugged for behaviors reclassified by psychiatry as “disease.”

As a result, CCHR is calling for an investigation into the psychiatric drugging of children in the United States. Individuals are invited to the center, located at 109 N. Fort Harrison Avenue in downtown Clearwater, to learn more about the dangers associated with psychiatric drugs as well as alternatives to medication. To learn more, please call 727-442-8820 or visit www.cchrflorida.org.

About CCHR: Initially established by the Church of Scientology and renowned psychiatrist Dr. Thomas Szasz in 1969, CCHR’s mission is to eradicate abuses committed under the guise of mental health and enact patient and consumer protections. It was L. Ron Hubbard, the founder of Scientology, who brought the terror of psychiatric imprisonment to the notice of the world. In March 1969, he said, “Thousands and thousands are seized without process of law, every week, over the ‘free world’ tortured, castrated, killed. All in the name of ‘mental health.’”

Diane Stein
Citizens Commission on Human Rights of Florida
(727) 422-8820
email us here

Drugging Children—Did You Know?


Source: EIN Presswire

Dr. Jacquie Smiles Joins Groupon CEO Rich Williams for Nasdaq’s Opening Bell Celebration!

Dr. Jacqueline Fulop Goodling, creator of Dr. Smiles and leader in orthodontics joined Groupon CEO Rich Williams on December 4th to ring the opening bell.

I was extremely honored to be a part of this monumental moment and to be part of the resilient New York family of professionals who I shared the stage with.”

— Dr. Jacqueline Fulop-Goodling, D.M.D., P.C.

NEW YORK CITY , NEW YORK, UNITED STATES, December 18, 2017 /EINPresswire.com/ — Dr. Jacquie Smiles Joins Groupon CEO Rich Williams for Nasdaq’s Opening Bell Celebration!

Dr. Jacqueline Fulop Goodling, a.k.a., Dr.Jacquie Smiles, a leader in orthodontics and the National Invisalign Spokesperson joined Groupon CEO Rich Williams at Times Square on December 4th to ring the opening bell.

“I was extremely honored to be a part of this monumental moment and to be part of the resilient New York family of professionals who I shared the stage with.” Dr. Jacquie says.

Dr. Jacquie, an Orthodontist with several offices in New York, recently changed her vision to world-wide when she cracked the code on teeth whitening by creating a proprietary formula that eliminates the sensitivity so many people suffer from when whitening their teeth professionally.

“The two things I have heard repeatedly from patients in all the years of creating signature smiles is ‘whitening doesn’t work or my teeth are so sensitive that I can’t go through with it.’ ” She said.

Two years in the making and many trips to the lab in perfecting it, Dr. Smiles White will launch 2018 with an “ALL Gain No Pain” campaign to include a VIP student program for that confident, courageous, contagious smile. More importantly, with advice on gaining the courage to do ANYTHING from nailing that interview or going up to your crush!

In addition to making people smile wider, whiter and brighter, it’s really about what is going on inside. A courageous, contagious confident smile truly comes from within. This and always paying it forward by giving, is what Dr. Smiles is all about. The Dr. Smiles Foundation, formed by Dr. Jacquie and her husband Anthony, focuses on changing the world one smile at a time. Aside from giving of themselves and dental services for those in need, anti-bullying efforts and a Miles for Smiles run are included in 2018 initiatives.

“Dr. Smiles is more than just teeth whitening. Our membership programs help inspire, empower and coach people to achieve confidence and goals in personalized and powerful ways online,” said Mindy DiCrosta, CEO of Creative Connections Network and part of the Dr. Smiles team in developing the brand.

“Dr. Jacquie and her staff have expertise that is second to none and a warmth with their patients that simply doesn’t exist in so many practices today,” DiCrosta said. What she does for people personally and professionally is nothing short of amazing!

Many people don’t realize that maintaining good dental health is associated with so many things in addition to bad breath, known as halitosis, red or bleeding gums and loose teeth including:

1. Heart disease: Gum disease may increase the risk of heart disease. Gum disease also is believed to worsen existing heart disease.
2. Stroke: Gum disease may increase the risk of the type of stroke caused by blocked arteries.
3. Diabetes: People with diabetes and periodontal disease may be more likely to have trouble controlling their blood sugar, than diabetics with healthy gums.
4. Premature births: A woman who has gum diseases during pregnancy may be more likely deliver her baby too early and the infant may be more likely to be of low birth weight.

Actually, one in four people have bad breath and some studies have reported that approximately 50 percent of the adult population has it. In fact, it is estimated that nearly 60 million people are aware that they suffer from chronic halitosis in the United States.

About Dr. Jacquie- Dr. Smiles and IDDS LLC
Dr. Jacquie completed her DMD degree and orthodontic residency at Boston University and after graduation became the first female and youngest Director of B.U.’s Predoctoral Orthodontic Department. Dr. Jacquie has taught over 14,000 doctors, students and their teams in orthodontics throughout the world. She has lectured in North and South America, Europe, Asia, The Caribbean and the Middle East. As an Invisalign professor, Dr. Jacquie teaches and certifies students and orthodontic residents in dental schools and universities in the U.S. and Canada. Dr. Jacquie has a heart for charity and makes giving back a priority of all her business endeavors.

Connect with us on Facebook, Instagram or Twitter and share your experience.

Keeping up with Dr. Jacquie Smiles
The Dr. Smiles membership platform includes apps, social and motivational features, advice and personalized coaching that are connected to increasing confidence and empowering young people. With a global community of engagement and support, this helps people be accountable, adhere to changes and reaching their personal goals.

Further details can be found on the site at drsmiles.com and drjacquiesmiles.com.

Mindy DiCrosta
Dr. Smiles
(203) 223- 8795
email us here


Source: EIN Presswire

Continuous Glucose Monitoring Market to reach US$ 14.4 Billion by 2024

Coherent Market Insights

Coherent Market Insights

Coherent Market Insights is a leading market research Publisher which offers report on “Continuous Glucose Monitoring Market to reach US$ 14.4 Billion by 2024”.

SEATTLE, WASHINGTON, UNITED STATES, December 18, 2017 /EINPresswire.com/ — The global Continuous Glucose Monitoring Market (CGM) was valued at US$ 2,035.8 million in 2015 and is projected to reach US$ 14,414.1 million by 2024, according to a new report by published by Coherent Market Insights. CGM devices allow monitoring of glucose level during bedtime, noon, pre/post lunch, or before/after exercise, which is a major factor propelling growth of the continuous glucose monitoring market.

The global CGM market is undergoing a major technological change that is resulting in a major paradigm shift. Novel devices such as Eversense CGM and GlySens ICGM, which can be implanted for relatively long duration of time, are expected to experience major growth traction, while demand for conventional CGM systems is expected to decrease in the near future. Demand would be largely driven by increasing awareness among the diabetic patients, especially in emerging markets such as Brazil, India, Indonesia, China, Russia, and South Africa regarding the various benefits of using these systems in order to maintain a healthy life. Renewed and dedicated effort from manufacturers and governments across these countries is essential to increase patient awareness and educate them about the importance of regular glucose monitoring in order to keep a check on diabetes and related diseases.

Request Sample copy of report@ https://www.coherentmarketinsights.com/insight/request-sample/57

Continuous monitoring glucose devices have witnessed increased demand from critical care patients, in order to avoid complexities in health condition. As a result, the device has witnessed high adoption in ICU units, besides home care and clinic settings. However, calibration issues is one of the prominent factor inhibiting market growth.

Technology collaboration helps companies leverage technical expertise of the other party and is a key trend prevalent in this industry. For instance, Medtronic collaborated with Fitbit, Inc. to integrate the physical activity data of the person with glucose levels into its iPro2 myLog application. Similarly, Senseonics, Inc. launched Eversense, the world’s first long-term implantable CGM, in January 2016. The evolving technological trend is transforming the method of monitoring glucose in the body.

However, therapeutic decisions as an outcome of measurement from tissue (interstitial fluid) lacks accuracy. Therefore, market is witnessing increasing adoption of CGM devices to be used in conjunction with conventional blood glucose monitoring devices, as a tool for diabetes management rather than as a replacement for the same. Companies therefore, need to work on the mechanism of the CGM system to make it more reliable in terms of diagnosis of diabetes, rather than just a tool for management.

Key takeaways of the market:

Diabetes is now of the most prevalent diseases that affects millions of people worldwide. According to the International Diabetes Federation (IDF), the global diabetic population in 2015 was 415 million and is expected to reach 642 million by 2040. Increase in awareness among patients is expected to drive market growth at a high CAGR of 24.5% during the forecast period 2016 – 2024.

Among the various product types of CGM systems, namely sensors, transmitters, and insulin pumps, the transmitters segment dominated the market in 2015, with a share of over 50%; however, growth of the market is expected to be mainly driven by sensors segment during the forecast period (2016 – 2024). CGM devices are used by diabetics as well as critical care patients. Demand for CGM devices would be high amongst the diabetic patient population during the forecast period, primarily due to increasing health awareness which indirectly promotes real-time monitoring of glucose levels.

In 2015, North America was the largest market for CGM, contributing US$ 247.6 million towards overall market revenue. This was primarily attributed to increasing awareness about CGM coupled with presence of substantially large diabetic population in the region.

To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/continuous-glucose-monitoring-market-57

According to the International Diabetes Federation (IDF), Asia Pacific was home to over 50% of the global diabetic population in 2015, with the highest prevalence rates recorded in China and India. The potential for CGM systems is therefore very high in these countries. Moreover, with increasing patient awareness, growing demand for POC devices and increasing focus on health monitoring, demand for CGM devices is projected to grow rapidly in Asia Pacific at a CAGR of 14.9% over the forecast period.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Mr. Shah
Coherent Market Insights
+1-206-701-6702
email us here


Source: EIN Presswire

Microfluidic Market to Surpass US$ 13.8 Billion Threshold by 2025

Coherent Market Insights

Coherent Market Insights

Coherent Market Insights is a leading market research Publisher which offers report on “Microfluidic Market to Surpass US$ 13.8 Billion Threshold by 2025”.

SEATTLE, WASHINGTON, UNITED STATES, December 18, 2017 /EINPresswire.com/ — The Global Microfluidic Market, by Material Type (Silicon-Based Microfluidic, Glass-Based Microfluidic, Polymer-Based Microfluidic, and Others), by Application (In Vitro Diagnostic Devices, Drug Delivery Devices and Monitoring Devices), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 2.8 billion in 2016 and is projected to exhibit a CAGR of 19.4% over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Increasing adoption of microfluidic technology to produce miniaturized microfluidic chips used in molecular diagnosis and analysis, is expected to boost growth of the microfluidic market. For instance, in March 2016, 908 Devices Inc. launched, ZipChip, a microfluidic device that provides high quality separation possibilities to mass spectroscopy enabling fast analysis for a broader range of biomolecules.

Request Sample copy of report@ https://www.coherentmarketinsights.com/insight/request-sample/1086

Advancement in microfluidics technology such as lab-on-a-chip is expected to propel growth of the market

Advancement in microfluidic technology such as sample droplet production technique, microfluidic sensors, lab-on-a-chip, microfluidic enabled microscope, and microfluidic valve controller helps to further augment growth of the microfluidic market. Moreover technology advancement in microfluidic saves the time, eliminate the need of expensive laboratory robots and reduce the risk of sample loss and contamination. For instance, in February 2017, researchers at the Stanford University School of Medicine have developed a relatively cheap and reusable diagnostic lab-on-a-chip for medical diagnostic application, which is expected to enhance the diagnostic capabilities and would be a highly feasible option in emerging economies.

Rising adoption of microfluidic technology in drug delivery systems is expected to accelerate demand for microfluidics

Controlled drug delivery system deliver the drug at target sites, in desired quantity, and on time thus, enhancing drug efficiency, bioavailability, and pharmacokinetics while maintaining minimum side effects. Microfluidic-based devices are adopted significantly for micro and nano-scale drug delivery, maintaining the physiochemical characteristics of drug, at the target location. For instance, researchers at the Massachusetts Eye and Ear Infirmary, Harvard Medical School and Charles Stark Draper Laboratory in Massachusetts developed microfluidic based automated micropump device for direct delivery of drugs into the perilymph fluid within the cochlea- an auditory portion of the inner ear.

Key players in the microfluidic market are emphasizing on introducing innovative solutions based on microfluidic technology for a wide range of applications. For instance, in November 2017, Dolomite Bio introduced Nadia- a single-cell platform for single-cell RNA sequencing. Nadia is droplet microfluidic based instrument that can generate 6,000 single-cell libraries per sample in just 15 minutes. It also aids researchers to run multiple samples parallelly.

Dolomite Bio combines the microfluidic technology with automated temperature control and cell/bead agitation in single instrument that delivers highly precise and reliable results. OPKO Health, Inc., in November 2017 submitted the Premarket Approval (PMA) application to US FDA for Claros 1 immunoassay analyzer. Claros 1 immunoassay analyzer is a diagnostic instrument system, which uses microfluidics technology to provide quick and quantitative blood test result in just 10 minutes by eliminating the need of external reagent, instrument calibration and maintenance.

Key Takeaways of the Microfluidic Market:

The global microfluidic market is expected to exhibit a CAGR of 19.4% over the forecast period, owing to the increased cardiovascular disease. For instance, in 2014, cardiovascular disease was the leading cause of death in China, accounting for around 42.60% and 44.52% of all deaths in rural and urban areas respectively. The other factors effecting the rise in microfluidic market are, increasing geriatric population and advancement in POC testing devices.

Among materials, the polymer-based microfluidic material segment is expected to account for major share over the forecast period. This is attributed to cost-effective, simple, and disposal advantage of these materials for total analysis system and lab-on-a-chip (LOC) devices.

Among application, the drug delivery devices segment is expected to be dominant in the microfluidic market over the forecast period, owing to factors such as safe, user-friendly, and controlled drug delivery of biomolecules of the systems.

Browse 30 Market Data Tables and 35 Figures spread through 190 Pages and in-depth TOC on “Microfluidic Market”- Global Forecast to 2025

To know the latest trends and insights prevalent in the Microfluidic market, click the link below:
https://www.coherentmarketinsights.com/market-insight/microfluidic-market-1086

Some of the major players operating in the global microfluidic market are Abbott Laboratories, Agilent Technologies, Thermo Fisher Scientific Inc., Qiagen N.V., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Fluidigm Corporation, Danaher Corporation, PerkinElmer Inc., Siemens Healthcare GmbH, and Micronit Microfluidic BV

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Mr. Shah
Coherent Market Insights
+1-206-701-6702
email us here


Source: EIN Presswire

Uveitis Treatment Market to Surpass US$ 900 Million Threshold by 2025

Coherent Market Insights

Coherent Market Insights

Coherent Market Insights is a leading market research Publisher which offers report on “Uveitis Treatment Market to Surpass US$ 900 Million Threshold by 2025”.

SEATTLE, WASHINGTON, UNITED STATES, December 18, 2017 /EINPresswire.com/ — The Global Uveitis Treatment Market, by Treatment (Corticosteroids, Immunosuppressant, Monoclonal Antibodies, Cycloplegic Agents, Antibiotics, Antivirals, Antifungals, and Analgesics), by Disease Type (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, and Panuveitis), by Cause (Infectious Uveitis and Non-infectious Uveitis) and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 555.51 million in 2016 and is projected to exhibit a CAGR of 6.0% over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Surge in incidence of autoimmune disease is expected to be a factor for increasing demand for uveitis treatment.

Request Sample copy of report@ https://www.coherentmarketinsights.com/insight/request-sample/1094

Corticosteroids are emerging as a potential option for the treatment of uveitis and is expected to propel growth of the global uveitis treatment market. According to a study published in the Journal of Ophthalmology in 2014, it was observed that 88% of the patients suffering with Uveitis can be cured with the help of sustained-release intraocular corticosteroids. According to the Clinical Investigation Department of the Open Access Journals, 2013, number of research studies on various new treatments by companies and research institutes for treatment of uveitis is increasing, which is known to be one of the leading cause of blindness in the U.S. Treatments such as next-generation calcineurin inhibitors that inhibits T-cell proliferation are also being studied for potential treatment for uveitis.

Furthermore, a number of innovations in treatment of uveitis were reported in 2015–2017, through FDA approvals. For instance, AbbVie Pharmaceutical Company’s HUMIRA (adalimumab) received U.S. FDA approval in June 2016, which is the first and only FDA-approved non-corticosteroid therapy for non-infectious intermediate, posterior and Panuveitis. Among disease types, the anterior uveitis treatment segment is expected to witness significant traction over the forecast years owing to increasing prevalence of chronic diseases such as eye trauma, mumps and rubella. Moreover, anterior uveitis is the most commonly encountered type of uveitis among the other types and is another factor driving growth of the segment.

North America is expected to be the dominant region in the global uveitis treatment market over the forecast period. This is attributed to a large number of regional companies having their uveitis treatment drugs in pipeline. For instance, the EGP-437 developed by Eyegate Pharmaceuticals for the treatment of anterior uveitis is now in Phase III studies of clinical trials and is expected to complete their clinical trials by February, 2018. Various other factors contributing for growth of the market in North America are increasing prevalence of uveitis, rising aging population, and growing companies and government initiatives to reduce diseases associated with eyes. For instance, a Foundation Fighting Blindness partnered by Genentech — a member of Roche Group — Regeneron and The Allergen Foundation started a campaign in 2014 — Envision 20/20. This campaign was started in order to end blindness and raise funds necessary for current and future research to develop treatments for eye diseases. It raised over US$ 111 Million for retinal disease research till June 2016. Asia Pacific market is expected to witness significant growth over the forecast period and this can be attributed towards rise in incidence of chronic diseases as well as increasing local companies investing on development of novel biologics for the treatment of uveitis.

Key Takeaways of the Uveitis Treatment Market:

The global uveitis treatment market is expected to exhibit a CAGR of 0% over the forecast period, owing to development of innovative uveitis drugs in the established markets in North America and Europe and emerging market in Asia Pacific
Among treatments, monoclonal antibodies segment is expected to gain significant traction over the forecast period owing to high efficacy of these drugs for the treatment of uveitis. However, corticosteroids is the most promising treatment in the current market scenario due to its success rate.

Among disease types, anterior uveitis is expected to hold a dominant position in the market as it is the most commonly occurring disease type as compared to the other disease types.

Browse 35 Market Data Tables and 30 Figures spread through 170 Pages and in-depth TOC on “Uveitis Treatment Market”- Global Forecast to 2025

To know the latest trends and insights prevalent in the Uveitis Treatment Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/uveitis-treatment-market-1094

Some major players operating in the global uveitis treatment market are AbbVie, Inc., Novartis AG, Eyegate Pharmaceuticals, Inc., Santen Pharmaceuticals, Allergan Plc, Regeneron Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., and Alimera Sciences.
About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Mr. Shah
Coherent Market Insights
+1-206-701-6702
email us here


Source: EIN Presswire

Respiratory Inhalers Market to Surge Past US$ 44.8 Billion by 2025

Coherent Market Insights

Coherent Market Insights

Coherent Market Insights is a leading market research Publisher which offers report on “Respiratory Inhalers Market to Surge Past US$ 44.8 Billion by 2025”.

SEATTLE, WASHINGTON, UNITED STATES, December 18, 2017 /EINPresswire.com/ — The Global Respiratory Inhalers Market, by Product Type (Dry Powder Inhalers (Single Unit Dose, Multi Dose and Multi Unit Dose), Metered Dose Inhalers and Nebulizers (Compressed, Mesh and Ultrasonic Inhalers), by Application (Asthma, Chronic Obstructive Pulmonary Disease, Pulmonary Arterial Hypertension and Cystic Fibrosis), by Technology (Digital and Manual), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 27,424.4 million in 2016 and is projected to exhibit a CAGR of 5.7% over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights.

Chronic obstructive pulmonary disease (COPD) is a life-threatening disease affecting the lungs characterized by acute breathlessness. In 2015, it was estimated that around 3 million deaths occurred due to sever Chronic Obstructive Pulmonary Disease (COPD), with 90% fatalities reported in low and middle income countries. The two most common forms of COPD include Chronic Bronchitis and Emphysema. According to American Lung Association (ALA), in 2011, over 24 million people in the U.S. suffered from COPD, including 10 million Chronic Bronchitis and over 4.7 million Emphysema cases. The major reason for chronic obstructive pulmonary disease is exposure to tobacco smoke through active or passive smoking. Most chronic obstructive pulmonary disease cases are preventable by avoiding tobacco smoking. However, countries need to adopt the WHO Framework Convention on Tobacco Control (WHO-FCTC) and follow the MPOWER package of measures so that non-smoking becomes the norm globally.

Request Sample copy of report@ https://www.coherentmarketinsights.com/insight/request-sample/227

Asthma is also one of the prime conditions leading to respiratory, disease which is characterized by recurring attacks of panting and wheezing. The severity and frequency of asthma varies according to individual. According to Center for Disease Control and Prevention (CDC), in 2015, 25 million people (1 in 13) in the U.S. were suffering from asthma. Under 18 age group, 6.2 million people suffered from asthma. Each year asthma accounts for 14.2 million physician office visits, and 1.8 million emergency visits.

Browse 32 Market Data Tables and 25 Figures spread through 195 Pages and in-depth TOC on Respiratory Inhalers Market by Product Type (Dry Powder Inhalers (Single Unit Dose, Multi Dose and Multi Unit Dose), Metered Dose Inhalers and Nebulizers (Compressed, Mesh and Ultrasonic Inhalers), by Application (Asthma, Chronic Obstructive Pulmonary Disease, Pulmonary Arterial Hypertension and Cystic Fibrosis), by Technology (Digital and Manual), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2025

According to Canadian Lung Association (CLA), in 2014, 2.5 million people in Canada suffered from asthma, including 1 million males and 1.4 million females. The number of people having asthma was 0.9 million in Ontario, 0.6 million in Quebec, 0.3 million in British Colombia, and Alberta states of Canada. According to Health and Safety Executive (HSE), an U.K based organization, each year in the U.K 200 to 300 new cases of occupational asthma, 4,000 COPD deaths, 200 to 300 new cases of Pneumoconiosis, and 20-50 new cases of Silicosis were reported. In 2015, it also reported 2,542 mesothelioma and 467 asbestos related deaths.

To know the latest trends and insights prevalent in the Respiratory Inhalers Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/respiratory-inhalers-market-227

Inhalers play a pivotal role in treatment of asthma and chronic obstructive pulmonary disease. The importance of the inhalation is delivery of medicines that directly acts on air passage and lungs. This signifies the higher concentrations of drug at target site, with lower systemic exposure thus also have low adverse effects than the oral or intravenous administration of drug. The drawback of inhalers are that it leads to suboptimal use and low efficacy. The design of inhalers also plays an important role in drug deposition, the characteristics of the inhaled medicine, and on the ability of the patient to use the device.

Key takeaways of the market:

The global respiratory inhalers market is expected to expand at a CAGR of 7% during the forecast period (2017–2025) as there exists a huge unrealized market especially in Asia Pacific, Latin America, Middle East and Africa
Asthma, a therapeutic application segment is expected to dominate the market throughout the forecast period with increasing prevalence of asthma

North America is expected to dominate the market, owing to the increasing usage of smart inhalers during the forecast period
Some of the major players involved in global respiratory inhalers market are AstraZeneca, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc, Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding and Teva Pharmaceutical Industries Ltd.

The key players are focusing on combinational therapies, which will drive the market forward

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Mr. Shah
Coherent Market Insights
+1-206-701-6702
email us here


Source: EIN Presswire

Implantable Drug Delivery Devices Market to Surpass US$ 18.3 Billion Threshold by 2025 Globally

Coherent Market Insights

Coherent Market Insights

Coherent Market Insights is a leading market research Publisher which offers research report on “Implantable Drug Delivery Devices Market”.

SEATTLE, WASHINGTON, UNITED STATES, December 18, 2017 /EINPresswire.com/ — The Global Implantable Drug Delivery Devices Market by Product Type (Drug infusion pumps, Intraocular drug delivery devices, Contraceptive drug delivery devices and Stents (Drug eluting stents and Bio absorbable stents), by Technology (Biodegradable Implants and Non Bio degradable Implants), by Application (Ophthalmology, Cardiovascular, Birth Control/Contraception and Others) and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 9,554.4 million in 2016 and is projected to exhibit a CAGR of 7.6% over the forecast period (2017 – 2025), as highlighted in a new report published by Coherent Market Insights. Factors such as growing aging population and incidence of diseases such as cardiovascular diseases, diabetic retinopathy are the driving factors for the growth of the global implantable drug delivery devices market over the forecast period.

Request Sample copy of report@ https://www.coherentmarketinsights.com/insight/request-sample/1103

Implantable drug delivery devices allow several site specific administration where the drug is needed most for the treatment. Devices allows for sustained release of a therapeutic agent and administer significant lower dose of the drug, which minimize side effects. In 2014, Alimera Sciences, Inc. received U.S. FDA approval for Iluvien for the treatment of diabetic macular edema. Iluvien implant is a tiny cylindrical tube inserted into the back of an eye. It is designed to provide a low daily dose of fluocinolone acetonide, a corticosteroid.

In 2015, the World Health Organization (WHO) estimated that around 17.7 million people died due to cardiovascular disease. Considering the huge patient pool, market players have developed bio absorbable stents. The bio-absorbable stents is expected to show an exponential growth during the forecast period due the fact that this stent is gradually resorb and cleared from the body. Bio absorbable stents overcomes the drawback of metal drug eluting stents. In 2017, Reva Medical Inc., received CE mark approval in Europe for Fantom (sirolimus-eluting bioresorbable coronary scaffold). CE marking is a certification mark that confirms with health, safety, and environmental protection standards for products sold within the European Economic Area (EEA).

Browse 38 Market Data Tables and 28 Figures spread through 144 Pages and in-depth TOC on Implantable Drug Delivery Devices Market by Product Type (Drug infusion pumps, Intraocular drug delivery devices, Contraceptive drug delivery devices and Stents(Drug eluting stents and Bio absorbable stents)), by Technology (Biodegradable Implants and Non Bio degradable Implants), by Application (Ophthalmology, Cardiovascular, Birth control/Contraception and Others) and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) – Global Forecast to 2025

To know the latest trends and insights prevalent in the Implantable Drug Delivery Devices Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/implantable-drug-delivery-devices-market-1103

Diabetic Macular Edema is a growing health problem and the number of cases are increasing due to prevalence of diabetes. According to National Diabetes Statistics, as of 2015 an estimated 30.3 million people of all ages had diabetes in U.S. Hence, manufacturers are actively working on research and development of the implant drug delivery devices field which are biodegradable. In 2014, Allergan received U.S. FDA approval for revised indication for Ozurdex (dexamethasone intravitreal implant) for the treatment of diabetic macular edema. Ozurdex is sustained-release biodegradable steroid implant.

Key Takeaways of the Implantable Drug Delivery Devices Market:

The global implantable drug delivery devices market is expected to exhibit a CAGR of 6% over the forecast period (2017 – 2025), owing to the growth in potential markets, especially in Asia Pacific and Latin America. North America accounted for major market share in 2016

Robust developments in the biodegradable implant products is expected to drive the implantable drug delivery devices market

Cardiovascular application hold the major market share and will show rapid growth due to the introduction of bio-absorbable stents in 2012, which in turn is expected to boost the growth of implantable drug delivery devices market

Some major players operating in the implantable drug delivery devices market are Boston Scientific Corporation, Bayer Healthcare, Medtronic, Allergan plc, Abbott Laboratories, Bausch and Lomb Inc., Elixir Medical Corporation, Riva Medical Inc., Merck & Co., Inc and Alimera Sciences

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Mr. Shah
Coherent Market Insights
+1-206-701-6702
email us here


Source: EIN Presswire

Protein Assays Market to Surge to US$ 3.65 Billion by 2025

Coherent Market Insights

Coherent Market Insights

Coherent Market Insights is a leading market research Publisher which offers research report on “Protein Assays Market to Surge to US$ 3.65 Billion by 2025”.

SEATTLE, WASHINGTON, UNITED STATES, December 18, 2017 /EINPresswire.com/ — The Global Protein Assays Market, by Product Type (Reagents and Kits, Instruments), by Technology Type (Absorbance-based Protein Assays, Colorimetric Protein Assays, Fluorescence-based Protein Assays), by Assay Type (Dye Binding Assays, Copper-Ion based Assays, Test Strip based Assays and Other Protein Assays) and by End User (Pharmaceutical and Biotechnology Companies, Clinical Laboratories, Hospitals and Academic Research Institutes) was valued at US$ 1,384.7 million in 2016 and is projected to exhibit a CAGR of 11.5% over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights.

Request Sample copy of report@ https://www.coherentmarketinsights.com/insight/request-sample/1087

Protein quantification is a process in protein extraction in biochemistry and molecular biology labs that involves protein extraction, analysis, or labeling. Quantification of protein is required for protein sample and analysis by electrophoresis or chromatography or any other immunochemical techniques. Commonly used protein assays are Bradford, Lowry, BCA, and UV spectroscopic protein assays. In April 2017, Millipore Sigma launched a new Single Molecule Counting Platform, SMCxPROTM, which is based on the principle of immunoassay and it enables precise and sensitive detection over conventional methods. Increasing investments of pharmaceutical companies in protein assays is leading to development of various drugs. Protein assays initiatives have led to new discoveries and development of treatments tailored for specific characteristics such as genetic makeup or genetic profile of an individual tumor that helps to offer relatively better and effective treatment methods. In 2015, According to a publication by Pharmaceuticals Research and Manufacturers of America (PhRMA) — a trade group representing companies in the pharmaceutical industry in the U.S.— the member organizations (pharmaceutical companies) of PhRMA invested around US$ 58.8 billion on R&D, accounting for the largest of all the biopharmaceutical R&D spending in the U.S, in 2015.

Browse 29 Market Data Tables and 33 Figures spread through 180 Pages and in-depth TOC on " Protein Assays Market, by Product Type (Reagents and Kits, Instruments), by Technology Type (Absorbance based Protein Assays, Colorimetric Protein Assays, Fluorescence based Protein Assays), by Assay Type (Dye Binding Assays, Copper-Ion based Assays, Test Strip based Assays and Other Protein Assays), by End User (Pharmaceutical and Biotechnology Companies, Clinical Laboratories, Hospitals and Academic Research Institutes) and by Region – Global Forecast to 2025"

Asia Pacific market is expected to witness highest growth in the global protein assays market over the forecast period, owing to rising application of protein content determination in pharmacy and biotechnology. Increasing private-public partnership for genetic analysis has aided in the market growth. Rising biotechnology and life sciences sector in this region as well as increasing focus on research and development by the top market players is another factor for growth of the market. For instance, in January, 2016, Thermo Fisher Scientific Inc. acquired Affymetrix to strengthen its position in biosciences and genetic analysis as well as extend geographic reach of Affymetrix’s products by leveraging Thermo Fisher’s market presence and infrastructure in Asia Pacific, particularly China.

Various new biomarker identification systems and emerging new uses for protein assays provided opportunities to the players in the global protein assay market. For instance, in June 2017, Gyros Protein Technologies AB launched a new version of its anti-drug antibody (ADA) solution for the immunogenicity segment. Gyrolab ADA solution enables to automatically run drug-tolerant ADA assays in a time efficient way reducing hands-on time, using small volumes of patient samples and reagents, and reducing run-times.

Manufacturers are likely to focus on launching systems, which are expected to help understand protein structures and functions, with tools to characterize post-translational modifications, localization, and expression control including epigenetic mechanisms. In June 2015, Thermo Fisher Scientific Inc. introduced Orbitrap Fusion Lumos Tribrid mass spectrometer and in 2017, it launched Integrated Ultraviolet Photo separation (UVPD) that enables specialists to perform substantial and little atom structure assurance on a Lorentz focus (LC) time scale; and new advanced peak determination (APD) calculation that is intended to enhance execution of most proteomic work processes with high peptide and protein ID rates.

To know the latest trends and insights related to protein assays market, click the link below:
https://www.coherentmarketinsights.com/market-insight/protein-assays-market-1087

Key Takeaways of the Protein Assays Market:

The global protein assays market is expected to exhibit a CAGR of 11.5% over the forecast period (2017–2025). This is attributed to increasing collaborations among pharmaceutical companies, academic researchers, regulators, and government organizations across various regions.

Among product type, reagents and kits segment is expected to account for the largest share in the global protein assay market over the forecast period. This is attributed to quick and ready-to-use modifications and the requirement of repeat purchase of reagents.

Among technology types, absorbance-based segment is expected to be largest contributor in terms of revenue to the global market over the forecast period, and this is primarily attributed to expanding effectiveness and accuracy of absorbance-based proteins

Some of the major players involved in global protein assays market are Thermo Fisher Scientific Inc., GE Healthcare, Merck KGaA, Bio-Rad Laboratories, Inc., Lonza, Abcam plc, PerkinElmer Inc., Bio-Techne, BioVision Inc., Cell Signaling Technology, Inc., and Geno Technology Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Mr. Shah
Coherent Market Insights
+1-206-701-6702
email us here


Source: EIN Presswire

Lab-On-A-Chip Market to Surpass US$ 10.25 Billion Threshold by 2025

Coherent Market Insights

Coherent Market Insights

Coherent Market Insights is a leading market research Publisher which offers report on “Lab-On-A-Chip Market to Surpass US$ 10.25 Billion Threshold by 2025”

SEATTLE, WASHINGTON, UNITED STATES, December 18, 2017 /EINPresswire.com/ — The global lab-on-a-chip market, by Application (Genomics, Proteomics, Diagnostics, and Drug Discovery), by Product Type (Reagents & Consumables, Software, and Instrument), by Technology (Microarrays and Microfluidics), by End User (Hospital, Diagnostic Labs, Academic and Research Institutes, Biotechnology, and Pharmaceutical Companies), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 4.09 Bn in 2016 and is projected to exhibit a CAGR of 10.8 % over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Increasing demand for diagnostic test and advancement in technology of lab-on-a-chip device, with wide number of applications, in turn is projected to fuel growth of the lab-on-a-chip market over the forecast period.

Request Sample copy of report@ https://www.coherentmarketinsights.com/insight/request-sample/515

Early detection of diseases help with effective treatment measures. However, diseases such as cancer are difficult to detect, as the symptoms are usually more detectable later stages. Scientists are facing challenges in capturing and analyzing the bioparticles of cancers, as they are very small in size, which fuels demand for lab-on-a-chip in cancer diagnosis. Increasing demand for lab-on-a-chip devices is mainly due to advancements in technology, portability, and re-configurability and applications. Some of the application of lab-on-a-chip devices are flow cytometer lab-on-a-chip for (HIV), immunoassay LoC for bacteria detection, real-time PCR detection chips, DNA chip, gene chip, and cellular analysis chip.

Furthermore, manufacturers are focusing on innovation to tap into emerging markets. For instance, in 2017, scientists of IBM Research are developing lab-on-a-chip nanotechnology that can separate and isolate bioparticles, which are around 20 nanometers in diameter. This in turn, gives access to identify DNA viruses and exosomes. This shows potential of lab-on-a-chip to analyze and reveal the presence of the diseases, even before a person shows the symptoms. Furthermore, in August 2017, Utah’s Brigham Young University used 3D printing technology and microfluidics collectively to develop the smallest viable 3D printed microfluidic device, which can be effective below 100 micrometers, indicating a major innovation in the lab-on-a-chip market.

Browse 30 Market Data Tables and 28 Figures spread through 160 Pages and in-depth TOC on Lab-On-A-Chip Market, by Application (Genomics, Proteomics, Diagnostics, and Drug Discovery), by Product Types (Reagents & Consumables, Software, and Instrument), by Technology (Microarrays and Microfluidics), by End User (Hospital, Diagnostic Labs, Academic and Research Institutes, Biotechnology, and Pharmaceutical Companies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2025

To know the latest trends and insights prevalent in the Lab-on-a-chip market, click the link below:
https://www.coherentmarketinsights.com/market-insight/lab-on-a-chip-market-515

Major players in the healthcare sector are adopting novel technologies to deliver better care. In October 2017, Micronit, Axxicon and Helvoet collaborated to offer a leading development and manufacturing package to support the growing demand for high volume polymer microfluidic products. This is majorly due to rapid development of diagnostic systems by the health care industry. For instance, Micronit provides innovative lab-on-a-chip and MEMS solutions using micro and nanotechnologies.

Furthermore, lab-on-a-chip use smartphones to quickly detect multiple pathogens. In October 2017, the University of Illinois at Urbana-Champaign and University of Washington at Tacoma has developed a novel platform to diagnose infectious diseases at the point-of-care, using a smartphone as the detection instrument.

Key takeaways of the market:

The global lab-on-a-chip market is expected to exhibit a CAGR of 8% over the forecast period (2017–2025), owing to rise in chronic diseases.

Asia Pacific is expected to exhibit a highest growth rate, in terms of revenue, in the global lob-on-a-chip market over the forecast period. This is due to increase in prevalence of chronic diseases such as tuberculosis, which in turn fuels growth of the market in the region. The World Health Organization (WHO) estimated that of the 9 million people who developed TB in 2013, 56% were in the South-East Asia and Western Pacific Regions.

Among product types, instrument segment accounted for 50.42% share of the lab-on-a-chip market in 2016
Some major players operating in the global lab-on-chip market are Takara Bio Inc., Nobel Biocare Services AG, Bio-Rad Laboratories Inc., PerkinElmer Inc., and Cepheid Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Mr. Shah
Coherent Market Insights
+1-206-701-6702
email us here


Source: EIN Presswire

Global Enteral Nutrition Market to Surpass US$ 19.31 Billion by 2025

Coherent Market Insights

Coherent Market Insights

Coherent Market Insights is a leading market research Publisher which offers report on “Global Enteral Nutrition Market to Surpass US$ 19.31 Billion by 2025”.

SEATTLE, WASHINGTON, UNITED STATES, December 18, 2017 /EINPresswire.com/ — Global enteral nutrition market was valued at US$ 13.11 billion in 2016, according to Global Enteral Nutrition Market, by Disease Type (Standard and Chronic), by Age Group (Below 15, 15 to 30, 30 to 45, 45 to 60, and Above 60), by End-use Industry (Hospitals, Clinics, and Long Term Care Facilities), published by Coherent Market Insights. The enteral nutrition market is expected to register a CAGR of 4.47% over the forecast period (2017–2025), to reach US$ 19.31 billion by 2025.

Some of the major factors propelling growth of this market are growing global geriatric population and rising prevalence of chronic diseases including diabetes, cardiovascular diseases, cancer, and others. According to the Centers for Disease Control and Prevention (CDC), in 2016, chronic diseases accounted for most of the deaths in U.S. and are responsible for 7 out of 10 deaths among Americans each year. In addition to this, increasing cases of premature births and malnutrition is expected to support growth of the enteral nutrition market. According to the World Health Organization (WHO), globally, preterm birth is the leading cause of death in children under the age of 5 years and the countries including India, China, U.S., Nigeria, Pakistan, Indonesia, Brazil, Bangladesh and Philippines recorded the highest number of preterm births as of November 2017. Furthermore, increasing advancements in technology such as tubes manufactured from polyurethane or silicone coupled with the development of percutaneous endoscopic gastrostomy techniques and surge in demand for home care services are some of the other factors supporting growth of the market. According to the Agency for Clinical Innovation (ACI), approximately 9000 people received home enteral nutrition (HEN) therapy in New South Wales (NSW), in 2012.

Request Sample copy of report@ https://www.coherentmarketinsights.com/insight/request-sample/1115

Key Trends and Analysis of Enteral Nutrition Market:

Among disease type, chronic was the dominant segment in 2016, and is anticipated to record the fastest growing segment over the forecast period. The segment is further segment into renal, hepatic, diabetic, and others and involves the usage of these disease specific enteral nutrition formula.

Among age group, the market is segmented into below 15, 15 to 30, 30 to 45, 45 to 60, and above 60. Above 60 segment accounted for the largest share in the global enteral nutrition market in 2016, as chronic diseases are more prevalent in geriatric population. According to the data provided by National Council on Aging, in 2016, approximately 90% of the geriatric population suffered from least one chronic disease and nearly 75% suffer from least two. The most common chronic diseases include cancer, diabetes, heart disease, and stroke.

Key Takeaways of the Market:

North America held the dominant position in the global enteral nutrition market in 2016, and was valued at US$ 4.24 Bn, and is projected to register a CAGR of 3.70% in terms of revenue over the forecast period. This is majorly due to the high number of premature births in the region, which is one of the key factors fuelling growth of the enteral nutrition market. Children, born before the 32nd and 34th week of gestation are required to receive a nasogastric tube for feeding right after birth. According to the data provided by the National Center for Biotechnology Information (NCBI), North America witnessed a significant rise in preterm births in 2016. Further, this incidence has recorded a significant growth in the past 25 years. In addition, according to the Centers for Disease Control and Prevention (CDC), in 2016, 1 out of every 10 infants were preterm born in the U.S. This factor is one of the key factors responsible for high growth of the enteral nutrition market in North America.

Europe is expected to record a substantial growth in demand for enteral nutrition over the forecast period. The market is primarily driven by rising incidences of cancer and diabetes in the region. According to Coherent Market Insights, in 2016, over 2.4 million people in the U.K. were affected by cancer, which is anticipated to cross 3.7 million by the end of 2035. Further, according to International Diabetes Federation, in 2015, over 6.5 million in Germany were suffering from diabetes, which is anticipated to grow at a steady rate over the forecast period. These factors are expected to aid in growth of the market.

Major players operating in the global enteral nutrition market include Nestle S.A., Baxter International Inc., B. Braun Holding GmbH & Co. KG, Abbott Laboratories, Groupe Danone, Reckitt Benckiser Group Plc , Perrigo Company Plc., Meiji Seika Pharma Co. Ltd., and Fresenius Kabi AG.

Browse 180 market data tables* and 100 figures* on "Enteral Nutrition Market” – Global forecast to 2025.

To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/enteral-nutrition-market-1115

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Mr. Shah
Coherent Market Insights
+1-206-701-6702
email us here


Source: EIN Presswire